Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)

Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with... AbstractBackground:The focus of the study is to determine the prevalence of CYP2C19 alleles, associated with the risk of changes in the pharmacological response to clopidogrel and proton pump inhibitors in patients with acute coronary syndrome (ACS) and gastric ulcer from Russian and Yakut ethnic groups.Methods:The research included 411 patients with ACS (143 Russians and 268 Yakuts) and 204 patients with histologically confirmed gastric ulcer (63 Russians and 141 Yakuts). Genotyping of 681G>A and 636G>A polymorphisms was performed by using polymerase real-time chain reaction.Results:In both ethnic groups, Hardy-Weinberg equilibrium was followed in a distribution of alleles and genotypes in the population (p>0.05). The 681A allele frequency in the Yakut ethnic group was higher than in the Russian group: 17.53% vs. 8.39% (p=0.001). No statistically significant difference was found in the frequency of 636A in Yakuts and Russians with ACS: 3.92% vs. 3.50% (p=0.840). While comparing the frequency distribution of alleles 681A (13.49% vs. 14.54%, p=0.878) and 636A (7.94% vs. 7.80%, p=1) in patients with a gastric ulcer from Russian and Yakut ethnic groups, no significant difference was found in carrier frequency.Conclusions:The results of the present study may be helpful for developing guidelines for CYPC19 genotype-directed antiplatelet therapy for Yakut and Russian patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Metabolism and Drug Interactions de Gruyter

Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)

Download PDF
8 pages

Loading next page...
 
/lp/degruyter/pharmacogenetic-testing-by-polymorphic-markers-681g-a-and-636g-a-rv0cLxdAfH
Publisher
de Gruyter
Copyright
©2018 Walter de Gruyter GmbH, Berlin/Boston
ISSN
2191-0162
eISSN
2363-8915
DOI
10.1515/dmpt-2018-0004
Publisher site
See Article on Publisher Site

Abstract

AbstractBackground:The focus of the study is to determine the prevalence of CYP2C19 alleles, associated with the risk of changes in the pharmacological response to clopidogrel and proton pump inhibitors in patients with acute coronary syndrome (ACS) and gastric ulcer from Russian and Yakut ethnic groups.Methods:The research included 411 patients with ACS (143 Russians and 268 Yakuts) and 204 patients with histologically confirmed gastric ulcer (63 Russians and 141 Yakuts). Genotyping of 681G>A and 636G>A polymorphisms was performed by using polymerase real-time chain reaction.Results:In both ethnic groups, Hardy-Weinberg equilibrium was followed in a distribution of alleles and genotypes in the population (p>0.05). The 681A allele frequency in the Yakut ethnic group was higher than in the Russian group: 17.53% vs. 8.39% (p=0.001). No statistically significant difference was found in the frequency of 636A in Yakuts and Russians with ACS: 3.92% vs. 3.50% (p=0.840). While comparing the frequency distribution of alleles 681A (13.49% vs. 14.54%, p=0.878) and 636A (7.94% vs. 7.80%, p=1) in patients with a gastric ulcer from Russian and Yakut ethnic groups, no significant difference was found in carrier frequency.Conclusions:The results of the present study may be helpful for developing guidelines for CYPC19 genotype-directed antiplatelet therapy for Yakut and Russian patients.

Journal

Drug Metabolism and Drug Interactions – de Gruyter

Published: Jun 27, 2018

References

  • Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes
  • Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis
  • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
  • CYP2C19*2 and prognosis after an acute coronary syndrome: insights from a Portuguese center
  • A comparative study of CYP2C19 gene polymorphism in children living in the Astrakhanian region
  • CYP2C19 polymorphism influences Helicobacter pylori eradication
  • The complex admixture history and recent southern origins of Siberian populations
  • Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy
  • Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population
  • Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese
  • The study of cytochrome P-450 CYP2C19 gene polymorphisms in population of Tatars living in Republic of Tatarstan
  • Clopidogrel with or without omeprazole in coronary artery disease
  • Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population
  • Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy
  • Prevalence of CYP2C19*2 (cG681A,rs4244285) polymorphic markers in Dagestan mountaineers population, its role for pharmacotherapy individualization
  • Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
  • Frequencies the “slow” allele variants of the genes coding isoenzymes of cytochrome Р450 CYP2D6, CYP2C19, CYP2C9 in Karachaevs and Circassians
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI
  • Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
  • 25 Years of proton pump inhibitors: a comprehensive review
  • Cytochrome 2C19 enzyme polymorphism frequency in different indigenous ethnic groups in Russian Federation: a systematic review
  • Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome
  • Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
  • Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI
  • A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease
  • Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
  • Pharmacogenetics: from bench to byte – an update of guidelines
  • CYP2C19*2, CYP2C19*3, CYP2C19*17 Allele and genotype frequencies in clopidogrel-treated patients with coronary heart disease from the Russian population
  • Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
  • Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
  • Corrigendum: geographic population structure analysis of worldwide human populations infers their biogeographical origins
  • Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese
  • Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
  • Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
  • 25 Years of proton pump inhibitors: a comprehensive review
  • Human evolution in Siberia: from frozen bodies to ancient DNA
  • A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry
  • Response to letter regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
  • CYP2C19*2, CYP2C19*3, CYP2C19*17 Allele and genotype frequencies in clopidogrel-treated patients with coronary heart disease from the Russian population
  • CYP2C19*2 and prognosis after an acute coronary syndrome: insights from a Portuguese center
  • Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
  • Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism
  • CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
  • Cytochrome P-450 polymorphisms and response to clopidogrel
  • Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
  • Corrigendum: geographic population structure analysis of worldwide human populations infers their biogeographical origins
  • CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
  • Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
  • Pharmacogenetics: from bench to byte – an update of guidelines
  • Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients
  • Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
  • The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
  • CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
  • Update on the pharmacogenomics of proton pump inhibitors
  • Frequencies the “slow” allele variants of the genes coding isoenzymes of cytochrome Р450 CYP2D6, CYP2C19, CYP2C9 in Karachaevs and Circassians
  • A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease
  • Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update
  • CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
  • Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
  • Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis
  • CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
  • Update on the pharmacogenomics of proton pump inhibitors
  • Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients
  • Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism
  • Cytochrome 2C19 enzyme polymorphism frequency in different indigenous ethnic groups in Russian Federation: a systematic review
  • Prevalence of CYP2C19*2 (cG681A,rs4244285) polymorphic markers in Dagestan mountaineers population, its role for pharmacotherapy individualization
  • Rapid and ultra-rapid metabolizers with CYP2C19 *17 polymorphism do not respond to standard therapy with proton pump inhibitors
  • Clopidogrel with or without omeprazole in coronary artery disease
  • The study of cytochrome P-450 CYP2C19 gene polymorphisms in population of Tatars living in Republic of Tatarstan
  • Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome
  • Human evolution in Siberia: from frozen bodies to ancient DNA
  • CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
  • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
  • The complex admixture history and recent southern origins of Siberian populations
  • Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome
  • CYP2C19 polymorphism influences Helicobacter pylori eradication
  • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
  • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
  • Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
  • A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry
  • Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
  • The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
  • Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome
  • Rapid and ultra-rapid metabolizers with CYP2C19 *17 polymorphism do not respond to standard therapy with proton pump inhibitors
  • Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
  • Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update
  • Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
  • Response to letter regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
  • Cytochrome P-450 polymorphisms and response to clopidogrel
  • A comparative study of CYP2C19 gene polymorphism in children living in the Astrakhanian region
  • Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population